Genelux (GNLX) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Genelux (GNLX) has outperformed Jyong Biotech (MENS) over the past year, losing 56.3% versus a loss of 95.3%. Jyong Biotech is the larger company by market cap ($110.2 million vs $103.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | MENS |
|---|---|---|
| Share price | $2.17 | $1.45 |
| Market cap | $103.36M | $110.24M |
| 1-day change | -4.82% | -17.14% |
| YTD return | -50.23% | -63.29% |
| 1-year return | -56.25% | -95.28% |
| EPS (TTM) | $-0.88 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.00K | — |
| Revenue growth (YoY) | 0.00% | — |
| Net income (latest FY) | $-32.15M | $-4.67M |
| Operating margin | -415175.00% | — |
| Net margin | -401812.50% | — |
| 52-week high | $5.89 | $38.88 |
| 52-week low | $1.77 | $1.43 |
| Distance from 52-week high | -63.16% | -96.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +767.74% | — |
| Average volume | 333.31K | 44.23K |
| Shares outstanding | 47.63M | 74.23M |
| Employees | 25 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed MENS by 39.0 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
GNLX vs MENS FAQ
Which is bigger, Genelux or Jyong Biotech?
Jyong Biotech (MENS) is larger, with a market capitalization of $110.24M compared with $103.36M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or MENS?
GNLX returned -56.25% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.